Title : Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.

Pub. Date : 2020 Apr 6

PMID : 32252811






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications. Everolimus CREB regulated transcription coactivator 1 Mus musculus
2 Based on results of the BOLERO-2 trial, the mTORC1 inhibitor everolimus in combination with the steroidal aromatase inhibitor (AI) exemestane has become a standard treatment for patients with HR+ HER2- mBC resistant to prior non-steroidal AI therapy. Everolimus CREB regulated transcription coactivator 1 Mus musculus
3 Therefore, two different molecules targeting the PI3K/AKT/mTORC1 axis, namely everolimus and alpelisib, are available for patients progressing on/after previous AI treatment, but it is unclear how to optimize their use in the clinical practice. Everolimus CREB regulated transcription coactivator 1 Mus musculus